The aberrant expression of FLT3 tyrosine kinase is associated primarily with acute myeloid
leukaemia. This blood malignancy is often related to the onset of internal tandem …

FLT3 is considered a potential target of acute myeloid leukemia therapy. In this study, we
applied a computer-aided methodology unifying molecular docking and pharmacophore …

The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors
has emerged as a target-based alternative to traditional chemotherapy for the treatment of …

FMS-like tyrosine kinase 3 (FLT3) is mutated in∼ 30% of patients that suffer from acute
myeloid leukemia (AML). In about 25% of all AML patients, in-frame insertions are observed …

Abstract Over 30–35% of patients down with AML are caused by mutations of FLT3‐ITD and
FLT3‐TKD which keeps the protein activated while it activates other signaling proteins …

ABSTRACT Mutations in Fetal Liver Tyrosine Kinase 3 (FLT3) genes are implicated in the
constitutive activation and development of Acute Myeloid Leukaemia (AML). They are …

Background Mutations in the FMS-like tyrosine kinase 3 (FLT3) are associated with
uncontrolled cellular functions that contribute to the development of acute myeloid …

Flt3 is an oncogenic kinase involved in different types of leukemia. It is most prominently
associated with acute myeloid leukemia (AML). Flt3-specific inhibitors have shown …

The aberrant expression of kinases is often associated with pathologies such as cancer and
autoimmune diseases. Like other types of enzymes, kinases can adopt active and inactive …

Based on a putative binding mode of quizartinib (AC220, 1), a potent FMS-like tyrosine
kinase 3 (FLT3) inhibitor in Phase III clinical development, we have designed de novo a …